Exicure announces strategic expansion into Parkinson’s disease
XCUR•Exicure intends to buy a 20%-100% equity interest in NeuroQ. NeuroQ will lead development and commercialization of X-CUE, with support from Exicure.
1. Expansion plans
Exicure intends to buy a 20%-100% equity interest in NeuroQ as it expands into Parkinson’s disease. NeuroQ will lead development and commercialization of X-CUE, with support from Exicure.




